NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
08/14/2026
Back to search
Official data from USPTO
SYNPLOGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
08/14/2026
Trademark type
Word
Nice classes
42
Filing date
08/22/2019
Registration date
08/04/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/14/2026
Last transaction
08/14/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Hyogo, JP
Examiner
VO, JULIE
Current location
Historical data usage
Holders and representatives
Holders
Synplogen Co., Ltd.
Representatives
Kumiko Ide Wenderoth, Lind & Ponack, L.L.P.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development relating to DNA synthesis technology; technical advisory services and * providing * information technology consulting services relating to DNA synthesis technology; research and development in the fields of bacteriologycytologyantibody technologychemistryimmunologygene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and developmentquality control for otherstechnical advisory services relating thereto in the fields of proteinantibodymicroorganismscells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; * providing * technical advisory services and information technology consulting services relating to genome synthesis technology; research and developmentquality control for otherstechnical advisory services relating thereto in the fields of proteinantibodymicroorganismscellsall with genome synthesis technology; research and development in the fields of bacteriologycytologyantibody technologychemistryimmunologygene expression systemsall with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testinginspection and research of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; development of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; * providing * technical advisory services relating to development of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; information technology services relating to development of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; testinginspection and research relating to medical treatment or medical technology with genome synthesis technology; * providing * information technology consulting services for testinginspection or research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testinginspection or research on agriculturelivestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others for scientific research purposes ; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; DNA sequence design services for scientific research purposes; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research
Publications
History of USPTO decisions and trademark events.
39 publications found
71AG
REGISTERED-SEC.71 ACCEPTED
08/14/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/10/2026
ES71
TEAS SECTION 71 RECEIVED
04/21/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/04/2025
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
02/17/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
12/24/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/30/2022
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
04/25/2022
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
04/24/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
02/05/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/12/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/25/2020
FIMP
FINAL DISPOSITION PROCESSED
11/25/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/04/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
08/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/19/2020
PUBO
PUBLISHED FOR OPPOSITION
05/19/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/29/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/13/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/23/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/23/2020
ALIE
ASSIGNED TO LIE
03/19/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/12/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/31/2020
GNRT
NON-FINAL ACTION E-MAILED
01/31/2020
CNRT
NON-FINAL ACTION WRITTEN
01/31/2020
RFNT
REFUSAL PROCESSED BY IB
01/17/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/14/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/14/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/14/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/02/2020
RFRR
REFUSAL PROCESSED BY MPU
01/02/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/04/2019
CNRT
NON-FINAL ACTION WRITTEN
12/03/2019
MAFR
APPLICATION FILING RECEIPT MAILED
11/26/2019
DOCK
ASSIGNED TO EXAMINER
11/22/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/22/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/21/2019
Continuous trademark protection
Get notified about every new filing that threatens SYNPLOGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.